Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BMRA vs LNTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LNTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

LNTH Overall Winner 6-Pillar Tally: BMRA 0 – 6 LNTH Matrix Metrics: BMRA 1 – 9 LNTH

As of Nov 16, 2026, Lantheus Holdings, Inc (LNTH) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas LNTH carries 43.5/100 (HOLD) at $101.75 (15.4x Forward P/E, 16.9% operating margin).

  • Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. LNTH 43.5/100 HOLD), LNTH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (16.9% vs. -125.2% operating margin) and revenue trajectory (+1.5% vs. -8.3% YoY).
  • Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile LNTH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMRA vs LNTH
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.36
+0.0% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96
LNTH NASDAQ Head-to-Head Winner
Lantheus Holdings, Inc
In Vitro & In Vivo Diagnostic Substances
$101.75
+0.15% 1D
Market Cap $6.6B
TTM Revenue $1.56B
Forward P/E 15.4x
Beta / 30D Vol 0.45β · 5% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 42.0 Fund 49.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 66
RSI-14: 65.8 · SMA20: $100.69 · SMA50: $100.34

6-Pillar Scorecard Institutional Category Breakdown (BMRA 0 – 6 LNTH)

Columns: Metric · BMRA · LNTH
1. Valuation Multiples LNTH
Forward P/E N/M 15.4x
Trailing P/E N/M 25.3x
PEG Ratio N/M 0.61x
EV / Revenue 1.1x 4.2x
2. Growth & Scale LNTH
Revenue Growth (YoY) -8.3% +1.5%
Earnings Growth (YoY) +0.0% -19.5%
TTM Revenue (USD) $4.3M $1.56B
Market Cap $6.0M $6.6B
3. Profitability & Quality LNTH
Gross Margin 0.9% 61.3%
Operating Margin -125.2% 16.9%
Net Profit Margin -115.5% 17.3%
Return on Equity (ROE) -113.8% 21.8%
4. Balance Sheet & Cash Flow LNTH
Cash Generation (TTM) -$3.2M $387M
Cash Flow Margin -73.5% 24.8%
Net Cash / Leverage $1.1M Net Cash $59M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LNTH
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 7.2% (4th %ile)
Put/Call OI Skew N/A 0.87x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat LNTH
OpEx & R&D Intensity N/A 44.4% of Rev ($694M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMRA (1) vs LNTH (9)
Institutional Metric BMRA LNTH Criterion Row Edge
Market Capitalization
Scale
$6.0M $6.6B Larger Scale LNTH
Trailing P/E Ratio
Valuation
N/M 25.3x Lower Multiple LNTH
Forward P/E Ratio
Valuation
N/M 15.4x Lower Multiple LNTH
Revenue Growth (YoY)
Growth
-8.3% +1.5% Higher Growth LNTH
Operating Margin (TTM)
Profitability
-125.2% 16.9% Higher Margin LNTH
Net Profit Margin
Profitability
-115.5% 17.3% Higher Margin LNTH
Return on Equity (ROE)
Capital Efficiency
-113.8% 21.8% Higher ROE LNTH
52-Week Range Position
Momentum
5% ($1–$3) 83% ($51–$112) Stronger Trend LNTH
Beta / 30D Volatility
Risk Regime
0.67β · 62% Vol 0.45β · 5% Vol Lower Realized Risk LNTH
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite BMRA
Trailing 12M Revenue (USD)
Operating Scale
$4.3M $1.56B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.9% 61.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.1x EV/Rev 0.61x PEG · 4.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.2M ($1.1M Net Cash) $387M ($59M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LNTH +28.54 pp
BMRA: -26.49% · LNTH: +2.05%
3M Horizon LNTH +16.48 pp
BMRA: -15.0% · LNTH: +1.48%
6M Horizon LNTH +48.81 pp
BMRA: -39.56% · LNTH: +9.25%
1Y Horizon LNTH +137.14 pp
BMRA: -45.6% · LNTH: +91.54%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BMRA Revenue LNTH Revenue BMRA Op. Margin LNTH Op. Margin Margin Leader
FY2019 $10M $350M -46.4% 14.9% LNTH
FY2020 $10M $340M -41.0% -1.2% LNTH
FY2021 $10M $430M -104.2% -14.3% LNTH
FY2022 $20M $940M -24.0% 3.9% LNTH
FY2023 $10M $1.30B -135.3% 28.1% LNTH
FY2024 $10M $1.53B -117.6% 29.8% LNTH
FY2025 $10M $1.54B -96.7% 20.2% LNTH
FY2026 $0M N/A -119.5% N/A BMRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LNTH CONSOLIDATION
97d in phase · OBV DISTRIBUTION
Current IV 7.2%
IV Percentile 4th %ile
Put/Call OI Skew 0.87x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LNTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LNTH Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $6.6B market capitalization and 16.9% operating margin.
OpEx & R&D Reinvestment 44.4% of Rev ($694M)
90D Engineering Disclosures 0 Published

Investor FAQ BMRA vs LNTH Key Questions & Quantitative Answers

As of Nov 16, 2026, Lantheus Holdings, Inc (LNTH) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas LNTH carries 43.5/100 (HOLD) at $101.75 (15.4x Forward P/E, 16.9% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. LNTH 43.5/100 HOLD), LNTH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (16.9% vs. -125.2% operating margin) and revenue trajectory (+1.5% vs. -8.3% YoY). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile LNTH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LNTH leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with LNTH at +1.5% YoY revenue growth and -19.5% YoY earnings growth on $1.56B TTM revenue (61.3% gross margin, 16.9% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BMRA cumulative revenue shifted +0.0% while LNTH shifted +340.0%. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus 44.4% of Rev ($694M) (0 disclosures) for LNTH.

LNTH screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas LNTH trades at 15.4x Forward P/E, 25.3x Trailing P/E, 0.61x PEG, and 4.2x EV/Revenue (24.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus LNTH (21.8% ROE) capital efficiency.

In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, LNTH carries 7.2% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.87x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.45β · 5% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.